Breaking antibiotic resistance: second phase of research awarded to LGC Ltd
Antibiotic Research UK has awarded the next phase of its research into antibiotic resistance breakers to LGC Ltd following the successful raising of funds.
Antibiotic Research UK (ANTRUK, York, UK) recently reviewed research bids for the next phase of its research on screening for antibiotic resistance breakers against antibiotic resistance in Gram-negative bacteria. LGC Ltd (Middlesex, UK) was awarded the research following the applications from nine organizations, ranging from national and international contract research organizations to universities.
The research conducted will be to screen up to 100 already existing drugs for their ability to break antibiotic resistance. Four species of Gram-negative bacteria, P. aeruginosa, K. pneumoniae, A. baumannii and E. coli, will be screened against the five main classes of antibiotic used to treat these infections. These are colistin, tigecycline, ciprofloxacin, meropenem and gentamycin.
The tenders received for the research were reviewed by the Science Committee at ANTRUK, together with external assessors. They were scored using predetermined criteria and reviewed to decide which of the bids should be funded. The recommended bid was also reviewed by the charity’s Trustees.
The contract was awarded to LGC Ltd and the research is about to commence. Drugs screened from the first phase of research will be examined at significantly higher concentrations than in the original screen, aiming to find drugs that are usable in the clinic.
Read more about the first phase of research here.